natgillin/translations-raw huggingface dataset:
• Glaxo Operations UK Limited, trading as Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, United Kingdom Manufacturing authorisation issued on 30 June 1995 by the Medicine Control Agency, Market Towers, 1 Nine Elms Lane, Vauxhall, London SW8 5NQ, United Kingdom. 
• Glaxo Operations UK Limited, trži Glaxo Wellcome Operations Priory Street, Ware, Hertfordshire SG12 ODJ, Velika Britanija Dovoljenje za izdelavo zdravila izdano 30. junija 1995 s strani Medicine Control Agency, Market Towers, 1 Nine Elms Lane, Vauxhall, London SW8 5NQ, Velika Britanija.
• Skin Rashes (red, raised or itchy) - Occasionally, the skin rash may be severe and you may have to stop taking this medicine. 
• Kožni izpuščaj (rdeč, privzdignjen nad nivo kože ali srbeč).Kožni izpuščaj je lahko občasno tudi hud in morda boste morali prenehati jemati to zdravilo.
- Please speak with your doctor if you have a history of liver disease. 
- S svojim zdravnikom se pogovorite, če ste kdaj imeli jetrno bolezen.
Clinical efficacy and safety have not been determined in this patient group. 
Pri tej skupini bolnikov klinična učinkovitost in varnost nista bili dognani.
Amprenavir is a competitive inhibitor of HIV-1 protease. 
Amprenavir je kompetitivni zaviralec proteaze virusa HIV-1.
The relationship between in vitro anti-HIV-1 activity of amprenavir and the inhibition of HIV-1 replication in humans has not been defined. 
Povezava med protiHIV-1 aktivnostjo amprenavirja in vitro in inhibicijo replikacije HIV-1 pri človeku ni bila določena.
Do not stop taking your medicine without first talking to your doctor. 
Zdravila ne smete prenehati jemati, ne da bi se prej posvetovali s svojim zdravnikom.
This medicine helps to control your condition, but it is not a cure for HIV infection. 
To zdravilo sicer pomaga obvladovati vašo bolezen, vendar pa okužbe z virusom HIV ne ozdravi.
Ask your doctor or pharmacist before taking any medicine. 
Posvetujte se z zdravnikom ali s farmacevtom preden vzamete katero koli zdravilo.
The effects of high fluticasone systemic exposure on ritonavir plasma levels is yet unknown. 
Učinki visoke sistemske izpostavljenosti flutikazonu na vrednosti ritonavirja v plazmi trenutno še niso znani.
In the event of overdosage, monitoring and management of acid-base abnormalities are recommended. 
V primeru prevelikega odmerjanja je priporočeno nadziranje in uravnavanje acido-baznih nepravilnosti.
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
• POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO Navedba smiselno ni potrebna.
No studies on the effects of Agenerase on the ability to drive and use machines have been done. 
Študije o učinkih zdravila Agenerase na sposobnost vožnje in upravljanje vozil in strojev niso bile izvedene.
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2). 
• POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Middlesex UB6 ONN United Kingdom 
Middlesex UB6 ONN Velika Britanija
The cause and long-term health effects of these conditions are not known at this time. 
Vzrok takšnih sprememb in njihovi dolgotrajni učinki na zdravstveno stanje trenutno niso poznani.
Ritonavir also inhibits CYP2D6 and induces CYP3A4, CYP1A2, CYP2C9 and glucuronosyl transferase. 
Ritonavir tudi zavira CYP2D6 in je induktor CYP3A4, CYP1A2, CYP2C9 ter glukuronozil transferaze.
Anticonvulsants (carbamazepine, phenobarbital, phenytoin) should be used with caution. 
Antiepileptike (karbamazepin, fenobarbital, fenitoin) je treba uporabljati previdno.
The safe use of Agenerase in pregnancy has not been established. 
Varnost uporabe zdravila Agenerase med nosečnostjo ni bila ugotovljena.
Appropriate antihistamines (e.g. cetirizine dihydrochloride) may reduce pruritus and hasten the resolution of rash. 
Ustrezen antihistaminik (npr. cetirizinijev diklorid) lahko omili srbež in pospeši resolucijo izpuščaja.
The choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1). 
Izbira amprenavirja mora temeljiti na individualnem testiranju virusne rezistence in podatkih predhodnega zdravljenja bolnikov (glejte poglavje 5.1).
Paediatrics: the pharmacokinetics of amprenavir in children (4 years of age and above) are similar to those in adults. 
Pediatrija: Farmakokinetične lastnosti zdravila Agenerase pri otrocih (starejših od 4 let) so podobne tistim pri odraslih.
Very common Common Uncommon Rare 
Zelo pogosti Pogosti Občasni Redki
However, there is little evidence from the exposure data in humans, both in clinical trials and from marketed use, to suggest that these findings are of clinical significance. 
Ne glede na vse je iz podatkov o izpostavi človeka tako v kliničnih študijah kot pri redni uporabi malo dokazov, ki bi nakazovali, da imajo navedene ugotovitve klinični pomen.
Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may have to be performed over a longer period. 
V primeru ukinitve kortikosteroida bo odmerek morda treba postopno zmanjševati daljši čas.
Each of these four genetic patterns associated with reduced susceptibility to amprenavir produces some cross-resistance to ritonavir but susceptibility to indinavir, nelfinavir and saquinavir is generally retained. 
Vsak od teh štirih genetskih vzorcev, ki so povezani z zmanjšano občutljivostjo za amprenavir, povzroča tudi določeno stopnjo navzkrižne odpornosti na ritonavir, občutljivost za indinavir, nelfinavir in sakvinavir pa se običajno ohrani.
Patients should be advised that Agenerase, or any other current antiretroviral therapy does not cure HIV and that they may still develop opportunistic infections and other complications of HIV infection. 
Bolnike je potrebno opozoriti, da zdravilo Agenerase ali katero koli drugo trenutno razpoložljivo protiretrovirusno zdravljenje ne ozdravi okužbe z virusom HIV, zato so še vedno možne oportunistične okužbe in drugi zapleti, povezani z okužbo z virusom HIV.
However, the possibility of anaphylactic reaction related to PEG 400 cannot be excluded. 
Vendar možnosti anafilaksijske reakcije povezane s PEG 400 ni mogoče izključiti.
- If you have had liver disease discuss this with your doctor. 
- Če ste kdaj imeli jetrno bolezen, se o tem pogovorite s svojim zdravnikom.
The dosage should therefore be reduced in these patients (see section 4.2). 
Takšnim bolnikom je torej potrebno odmerke zmanjšati (glejte poglavje 4.2).
In more than half of the reported cases, treatment with protease inhibitors was continued, or reintroduced if treatment had been discontinued. 
V več kot polovici poročanih primerov zdravljenje z zaviralci proteaz ni bilo prekinjeno ali pa se je po prekinitvi nadaljevalo.
Agenerase belongs to a group of antiviral medicines called protease inhibitors. 
Zdravilo Agenerase pripada skupini protivirusnih zdravil, ki se imenujejo zaviralci proteaz.
There are currently data on cross-resistance between amprenavir and other protease inhibitors for all 4 fosamprenavir resistance pathways, either alone or in combination with other mutations. 
Podatki o navzkrižni odpornosti med amprenavirjem in drugimi zaviralci proteaz so za vse štiri mehanizme odpornosti fosamprenavirja, same ali v kombinaciji z drugimi mutacijami.
You should not take more than 2800 mg per 
Na dan pa ne smete vzeti več kot 2800 mg.
Because of the potential for metabolic interactions with amprenavir, the efficacy of hormonal contraceptives may be modified, but there is insufficient information to predict the nature of the interactions. 
Ker obstaja možnost presnovnih interakcij z amprenavirjem, se lahko spremeni učinkovitost hormonskih kontraceptivov, vendar za predvidenje narave takšnih interakcij ni na razpolago dovolj podatkov.
Propylene glycol can be removed by hemodialysis. 
Propilenglikol se lahko odstrani s hemodializo.
- Patients of 4 years of age and older unable to swallow capsules: The dose will be calculated according to your weight by your doctor. 
- Bolniki, stari 4 leta in starejši, ki ne zmorejo pogoltniti kapsul: Glede na vašo težo bo odmerek preračunal zdravnik.
St John's wort (Hypericum perforatum) 
Šentjanževka (Hypericum perforatum)
However, this increase was not statistically significantly different from male control mice by appropriate tests. 
Kljub temu pa je bilo z ustreznimi testi ugotovljeno, da se to povišanje statistično značilno ne razlikuje od kontrolne populacije mišjih samcev.
Distribution: the apparent volume of distribution is approximately 430 litres (6 l/kg assuming a 70 kg body weight), suggesting a large volume of distribution, with penetration of amprenavir freely into tissues beyond the systemic circulation. 
Porazdelitev: Navidezni volumen porazdelitve znaša približno 430 litrov (6 l/kg pri telesni masi 70 kg), kar nakazuje na obsežen volumen porazdelitve in zmožnost prostega prehajanja amprenavirja v tkiva izven sistemske cirkulacije.
- In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
- Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS) in z oportunistično okužbo v anamnezi se lahko kmalu po začetku anti-HIV zdravljenja pojavijo znaki in simptomi vnetja povezani s prejšnjimi okužbami.
It might also be necessary to reconsider the treatment with Agenerase oral solution. 
Morda bo tudi potrebno ponovno preveriti upravičenost zdravljenja s peroralno raztopino Agenerase.
Before starting treatment with Agenerase, please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. 
Preden se pričnete zdraviti z zdravilom Agenerase, obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta.
A higher risk of lipodystrophy has been associated with individual factors such as older age, and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances. 
Večje tveganje za lipodistrofijo je bilo povezano z individualnimi dejavniki, kot je višja starost, ter z od zdravila odvisnimi dejavniki, kot je dolgotrajnejše protiretrovirusno zdravljenje, in z njimi povezanimi presnovnimi motnjami.
Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. 
Amprenavir se veže na aktivno mesto proteaze virusa HIV-1 in tako prepreči nastajanje virusnih gag in gag-pol poliproteinskih predhodnikov, kar ima za posledico tvorbo nezrelih in nekužnih virusnih delcev.
If you have any further questions on the use of this product, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom ali s farmacevtom.
Agenerase capsules also contain sorbitol (E420). 
Kapsule Agenerase vsebujejo tudi sorbitol (E420).
The impact of renal impairment on amprenavir elimination should be minimal therefore, no initial dose adjustment is considered necessary. 
Vpliv oslabljenega delovanja ledvic na izločanje amprenavirja je minimalen, zato prilagajanje začetnega odmerka ni potrebno.
480 soft capsules 
480 mehkih kapsul
No dose recommendations can be made regarding this combination. 
Za takšno kombinacijo ne moremo podati priporočenih odmerkov.
The evidence of efficacy of unboosted Agenerase was based on two uncontrolled clinical studies involving 288 HIV infected children aged between 2 and 18 years, 152 of whom were PI experienced. 
Dokaz učinkovitosti zdravila Agenerase brez okrepitve temelji na dveh nenadzorovanih kliničnih študijah, v kateri je bilo vključenih 288 z virusom HIV okuženih otrok, starih od 2 do 18 let.
Like all medicines, Agenerase can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Agenerase neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Concomitant use is not recommended (see section 4.4). 
Sočasne uporabe ne priporočamo (glejte poglavje 4.4).
Combination antiretroviral therapy may also cause raised lactic acid and sugar in the blood, hyperlipaemia (increased fats in the blood) and resistance to insulin. 
Kombinirano protiretrovirusno zdravljenje lahko povzroči tudi povišane vrednosti mlečne kisline in sladkorja v krvi, hiperlipemijo (povišanje maščob v krvi) in odpornost na insulin.
The metabolism of pravastatin and fluvastatin is not dependent on CYP3A4, and interactions are not expected with protease inhibitors. 
Presnova pravastatina in fluvastatina ni odvisna od CYP3A4, tako interakcije z zaviralci proteaz niso pričakovane.
This is very important, as taking some types of medicines at the same time as Agenerase can strengthen or weaken the effect of the medicines. 
To je zelo pomembno, saj lahko sočasno jemanje nekaterih vrst zdravil in zdravila Agenerase okrepi ali oslabi njihov učinek, kar lahko včasih pripelje do resnih zdravstvenih težav.
When treating HIV infection, it is not always possible to tell whether some of the undesirable effects that occur are caused by Agenerase, by other medicines taken at the same time or by the HIV disease. 
Pri zdravljenju okužbe z virusom HIV ni mogoče vedno vedeti, ali je vzrok neželenim učinkom zdravilo Agenerase, druga zdravila, ki jih jemljete sočasno, ali sama bolezen, vezana na okužbo z virusom HIV.
WHAT AGENERASE IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO AGENERASE IN ZA KAJ GA UPORABLJAMO
What Agenerase looks like and contents of the pack 
Izgled zdravila Agenerase in vsebina pakiranja
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with Agenerase is not recommended. 
Ker zvišane plazemske koncentracije zaviralcev HMG-CoA lahko povzročijo miopatijo, vključno z rabdomiolizo, se kombinacija teh zdravil z zdravilom Agenerase ne priporoča.
If these medicinal products are used concomitantly care is advised, and close clinical and virological monitoring should be performed since it is difficult to predict the effect of the combination of amprenavir and ritonavir on delavirdine. 
Ob sočasni uporabi teh zdravil svetujemo previdnost in temeljito klinično in virološko nadziranje, saj je učinek kombinacije amprenavirja in ritonavirja na delavirdin težko napovedati.
The systemic exposure to the dams associated with this finding was similar to exposure in humans, following administration of the recommended dose. 
Sistemska izpostavljenost brejih samic v tej študiji je bila približno enaka izpostavljenosti bolnic po zaužitju priporočenega odmerka.
Prior number of NRTIs taken [n (%)] 
Število predhodno uporabljenih NRTI-jev [n (%)]
- Children (4 to 12 years) and patients less than 50 kg body weight: the dose will be calculated according to your weight by your doctor. 
- Otroci (4 do 12 let) in bolniki s telesno težo, manjšo od 50 kg: Glede na vašo težo bo odmerek preračunal zdravnik.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis carinii pneumonia. 
Ustrezni primeri so citomegalovirusni retinitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis carinii povzročena pljučnica.
Soft capsule. 
Mehke kapsule.
Elderly: the pharmacokinetics of amprenavir have not been studied in patients over 65 years of age. 
Starejši: Farmakokinetičnih lastnosti amprenavirja niso preučevali pri bolnikih, starejših od 65 let.
The 50 mg and 150 mg capsules have been shown to be bioequivalent. 
Izkazalo se je, da so 50 mg in 150 mg kapsule bioekvivalentne.
Middlesex UB6 0NN United Kingdom 
Middlesex UB6 0NN Velika Britanija
1 Primary mutations were as defined by the IAS USA at the time of the original analysis, 2002 D30N, 
1 Primarne mutacije po definiciji IAS USA v času prvotne analize v letu 2002 so: D30N, M46I/L,
Antacids: on the basis of the data for other protease inhibitors, it is advisable not to take antacids at the same time as Agenerase, since its absorption may be impaired. 
Antacidi: Na osnovi podatkov za druge zaviralce proteaz je priporočljivo, da se antacidi ne jemljejo sočasno z zdravilom Agenerase, ker bi lahko prišlo do motenj absorpcije slednjega.
You may need additional factor VIII to control bleeding. 
Za obvladovanje krvavitev boste morda morali prejemati dodaten faktor VIII.
Resistance testing diagnostic companies have developed clinical phenotypic cut-offs for FPV/RTV that can be used to interpret resistance test results. 
Podjetja, ki razvijajo diagnostične teste za odkrivanje rezistence, so objavila klinične fenotipske mejne vrednosti za FPV/RTV, ki se jih lahko uporabi pri interpretaciji rezultatov testiranja rezistence.
Excipients: d-sorbitol (E420) 
Pomožne snovi: d-sorbitol (E420)
Alcohol and inhibitors of alcohol metabolism: Agenerase oral solution contains propylene glycol (550 mg/ml), which is primarily metabolised via alcohol dehydrogenase. 
Alkohol in zaviralci presnove alkohola: Peroralna raztopina Agenerase vsebuje propilenglikol (550 mg/ml), ki se primarno presnavlja s pomočjo alkoholne dehidrogenaze.
Interaction studies have been performed with amprenavir as the sole protease inhibitor. 
Študije interakcij so bile izvedene z amprenavirjem kot edinim zaviralcem proteaz.
Agenerase is prescribed for use in combination with other antiretroviral medicinal products. 
Zdravilo Agenerase se predpisuje za uporabo v kombinaciji z drugimi protiretrovirusnimi zdravili.
Absorption: after oral administration, amprenavir is rapidly and well absorbed. 
Absorpcija: Amprenavir se po peroralnem vnosu hitro in dobro absorbira.
Agenerase is also available as capsules. 
Zdravilo Agenerase je na voljo tudi v obliki kapsul.
Your doctor may monitor you for adverse reactions potentially related to the propylene glycol content of the Agenerase oral solution, especially when you have renal or hepatic disease. 
Zdravnik vas lahko nadzira glede možnih neželenih učinkov, povezanih z vsebnostjo propilenglikola v peroralni raztopini Agenerase, še posebno če imate ledvično ali jetrno bolezen.
For patients with renal failure, hepatic impairment or failure, children and pregnant women, see section 4.3. 
Glede bolnikov z odpovedjo ledvic, bolnikov z oslabljenim delovanjem ali odpovedjo jeter, otrok in nosečnic glejte poglavje 4.3.
Elevated transaminases 
zvišanje vrednosti transaminaz
Coadministration with Agenerase with or without ritonavir may cause a large increase in the concentration of this benzodiazepine. 
Sočasna uporaba zdravila Agenerase z ritonavirjem ali brez lahko vodi v visok porast koncentracij tega benzodiazepina.
Frequency categories for the events below have been based on clinical trials and postmarketing data. 
Kategorije pogostnosti navedenih neželenih učinkov temeljijo na podatkih kliničnih študij in spremljanja po pridobitvi dovoljenja za promet.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally. 
Na osnovi podatkov za druge zaviralce CYP3A4 je pričakovati, da bodo plazemske koncentracije midazolama ob peroralnem vnosu midazolama znatno višje.
If you suffer from liver disease and your doctor decides to use unboosted Agenerase capsules (that is without ritonavir), the dose of Agenerase may need to be adjusted. 
Če imate jetrno bolezen in se je zdravnik odločil za uporabo kapsul Agenerase brez dodatne okrepitve njihovega učinka (to je brez ritonavirja), bo morda potrebno odmerek zdravila Agenerase prilagoditi.
Therapy should be initiated by a physician experienced in the management of HIV infection. 
Zdravljenje mora uvesti zdravnik z izkušnjami v zdravljenju z virusom HIV okuženih bolnikov.
Similarly, amprenavir might also modify the pharmacokinetics of other medicinal products that share this metabolic pathway. 
Podobno lahko tudi amprenavir spremeni farmakokinetične lastnosti drugih zdravil, ki si delijo to presnovno pot.
Rifabutin: co-administration of amprenavir with rifabutin resulted in a 193 % increase in rifabutin AUC and an increase of rifabutin-related adverse events. 
Rifabutin: Sočasna uporaba amprenavirja z rifabutinom je imela za posledico zvečanje AUC rifabutina za 193 %, hkrati pa je tudi narasla pogostnost z rifabutinom povezanih neželenih učinkov.
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone). 
Razmisliti je treba o zmanjšanju odmerka glukokortikoida ob sočasnem skrbnem nadziranju lokalnih in sistemskih učinkov ali o zamenjavi z glukokortikoidom, ki ni substrat za CYP3A4 (npr. beklometazon).
Therefore, although food affects the extent and rate of absorption, the steady-state trough concentration (Cmin,ss) was not affected by food intake. 
Kljub temu da hrana vpliva na obseg in hitrost absorpcije, se minimalna koncentracija v stanju dinamičnega ravnovesja (Cmin,ss) zaradi hrane ne spremeni.
This will result in a fluctuation in the apparent volume of distribution of total active substance, but the volume of distribution of free active substance does not change. 
To vodi v fluktuacijo navideznega volumna porazdelitve celokupne učinkovine, volumen porazdelitve proste učinkovine pa se ne spreminja.
In toxicological studies with mature animals, the clinically relevant findings were mostly confined to the liver and gastrointestinal disturbances. 
Klinično pomembni izsledki toksikoloških študij na odraslih živalih se nanašajo predvsem na jetra in gastrointestinalne motnje.
The usual dose of Agenerase oral solution is 17 mg (1.1 ml) for each kg of body weight three times a day. 
Običajen odmerek peroralne raztopine Agenerase je 17 mg/ml (1,1 ml) na vsak kilogram telesne teže, trikrat dnevno.
Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels. 
Podatki o sočasni parenteralni uporabi midazolama in drugih zaviralcev proteaz nakazujejo možen 3- do 4-kratni porast plazemskih ravni midazolama.
Median CD4 (cells/ml) (range) 
Srednja vrednost števila celic CD4 (celice/ml) (razpon)
There are some medicines that you must not take with Agenerase (please see ‘Do not take Agenerase' for further information). 
Nekaterih zdravil ne smete jemati skupaj z zdravilom Agenerase (za dodatne informacije glejte 'Ne jemljite zdravila Agenerase').
Following multiple oral doses of amprenavir (1200 mg twice a day), there is no significant active substance accumulation. 
Po zaužitju več peroralnih odmerkov amprenavirja (1200 mg dvakrat dnevno) ni prihajalo do znatnega kopičenja učinkovine v telesu.
Pharmacotherapeutic group; protease inhibitor; ATC Code: J05A E05 
Farmakoterapevtska skupina: Zaviralci proteaz, Oznaka ATC: J05A E05
Heavily pre-treated children, unboosted Agenerase 
Predhodno intenzivno zdravljeni otroci, zdravilo Agenerase brez okrepitve
• Increases in triglycerides (a type of blood fat), changes in body shape because of fat redistribution, 
• Povečane vrednosti trigliceridov (vrsta maščobe) v krvi, spremembe telesne oblike zaradi spremembe v porazdelitvi telesnega maščevja.
The in vitro antiviral activity of amprenavir was evaluated against HIV-1 IIIB in both acutely and chronically infected lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and in peripheral blood lymphocytes. 
Protivirusna aktivnost amprenavirja proti HIV-1 IIIB in vitro je bila vrednotena na akutno in kronično okuženih limfoblastnih celičnih linijah (MT-4, CEM-CCRF, H9) in na limfocitih iz periferne krvi.